1. A199 EFFICACY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: RESULTS FROM THE OCTAVE CLINICAL TRIALS. (1st March 2018) Authors: Panés, J; Bressler, B; Colombel, J F; Lawendy, N; Maller, E; Zhang, H; Woodworth, D; Chan, G; Su, C Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 1(2018)Supplement 2 Page Start: 294 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP027 Efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: Results of the OCTAVE open study for tofacitinib 8-week induction non-responders. (16th January 2018) Authors: Feagan, B G; Dubinsky, M C; Lukas, M; Quirk, D; Nduaka, C I; Maller, E; Lawendy, N; Kayhan, C; Wang, W; Chan, G; Su, C Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S050 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DOP43 Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the OCTAVE open study for tofacitinib delayed responders. (25th January 2019) Authors: Rubin, D T; Dubinsky, M C; Lukas, M; Quirk, D; Nduaka, C I; Maller, E; Lawendy, N; Kayhan, C; Fan, H; Woodworth, D A; Chan, G; Su, C Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S050 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P252 Measuring the mediating effects of Mayo score components for tofacitinib on disease-specific quality of life in ulcerative colitis: data from the OCTAVE programme. (25th January 2019) Authors: Dubinsky, M; Bushmakin, A; DiBonaventura, M; Cappelleri, J; Salese, L; Maller, E; Armuzzi, A Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S222 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P388 Analysis of the impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis programme. (25th January 2019) Authors: Farraye, F A; Qazi, T; Kotze, P G; Moore, G T; Kayhan, C; Mundayat, R; Maller, E; Su, C; Soonasra, A Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S301 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P516 Efficacy and safety of tofacitinib retreatment for ulcerative colitis after treatment interruption: Results from the OCTAVE clinical trials. (16th January 2018) Authors: Panés, J; Bressler, B; Colombel, J -F; Lawendy, N; Maller, E; Zhang, H; Woodworth, D A; Chan, G; Salese, L; Su, C Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S366 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P531 Efficacy of tofacitinib maintenance therapy for ulcerative colitis in remitting patients vs. patients with clinical response after 8 weeks of induction treatment. (25th January 2019) Authors: Reinisch, W; Osterman, M T; Doherty, G; Marren, A; Woodworth, D A; Lawendy, N; Kwok, K; Maller, E; Su, C Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S378 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P685 Improvement in patient-reported Inflammatory Bowel Disease Questionnaire outcomes, and relationship with disease activity, in tofacitinib-treated patients with ulcerative colitis: Data from the OCTAVE clinical trials. (25th January 2019) Authors: Dubinsky, M C; Bressler, B; Armuzzi, A; Salese, L; DiBonaventura, M; Maller, E; Fan, H; Woodworth, D A; Su, C Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S462 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P699 The concordance of Short Form-36 Health Survey scores with Mayo scores in the tofacitinib ulcerative colitis clinical programme. (15th January 2020) Authors: Dubinsky, M C; Bushmakin, A G; Cappelleri, J C; Woolcott, J; Sharma, P; Maller, E; Salese, L; Armuzzi, A Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S566 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗